@article{oai:air.repo.nii.ac.jp:00001883,
 author = {Anbai, Akira and Koga, Makoto and Motoyama, Satoru and Sato, Yusuke and Jin, Mario and Matsuhashi, Tamotsu and Shibata, Hiroyuki and Ohtsuka, Kazunori and Hashimoto, Manabu},
 issue = {1},
 journal = {秋田医学},
 month = {Sep},
 note = {We evaluated the treatment outcomes of chemoradiotherapy for patients with unresectable advanced thoracic esophageal cancer. In total, 103 patients (99 men and 4 women) with unresectable cancer (stage IVA) were treated with chemoradiotherapy between April 2003 and December 2009. They ranged in age from 48 to 89 years, with a median age of 68 years. Two courses of chemotherapy (cisplatin［CDDP］ 40 mg/m^2 on Days 1 and 8 plus 5-fluorouracil［5-FU］ 400 mg/m^2 on Days 1 through 5 and on Days 8 through 12) and radiotherapy at doses of 59.4 to 66 Gy were administered. The mean follow-up period was 15.3 months (range, 2-88 months). The median overall survival was 13.9 months. The 2-year survival rate was 33.1% and the 3-year survival rate 17.0%. Complete response (CR) was obtained in 18 patients (17.5%). Nine of the 18 patients with CR developed recurrence. Severe hematological toxicities occurred, but were tolerable.},
 pages = {19--26},
 title = {TREATMENT OUTCOMES OF CHEMORADIOTHERAPY FOR PATIENTS WITH STAGE IVA THORACIC ESOPHAGEAL CANCER AT OUR CENTER},
 volume = {39},
 year = {2012}
}